NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/02/2026
Back to search
Official data from USPTO
PADAGIS NALOXONE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
06/02/2026
Trademark type
Combined
Nice classes
5, 20, 35, 44
Filing date
11/19/2024
Registration date
06/02/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/02/2026
Last transaction
06/02/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/10/2024
First use in commerce
10/10/2024
Drawing code
3
Owner type
16
Owner location
ALLEGAN, MI, US
Examiner
POLLACK, ALISON FRIEDBERG
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the stylized wording "Padagis" above the larger stylized wording "Naloxone" with a plus sign design above and to the right of the "e" in "Naloxone".
Holders and representatives
Holders
PADAGIS US LLC
Representatives
Andrea M. Porterfield Polsinelli PC
Technical classification
Nice Classes
Class 5Class 20Class 35Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicinal pharmaceutical preparations used as a narcotic antagonist for the treatment of opioid overdose; pharmaceutical preparationsopioid antagonists and narcotic antagonists for the treatment of opioid overdose; pharmaceutical and pharmaceutical drug preparations for use in treatment of opiateopioid or narcotic overdose; intranasal drug delivery devicesspray pump devices for nasal deliverydevices for nasal deliveryall being drug delivery agents in nasal spray form that facilitate the delivery of pre-filled pharmaceuticals preparationsopioid antagonists and narcotic antagonists and pharmaceutical and pharmaceutical drug preparations for use in treatment of opiateopioid or narcotic overdose; nasal spray preparations; Medical kitsnamely opioid overdose response kits comprising pharmaceutical preparations for use in treatment of opiateopioid or narcotic overdose and also including carrying casestraining kits containing nasal spray bottles sold emptystorage cabinets for medical kits of intranasal drug delivery devices
Class 20
Medicine cabinets
Class 35
Online retail store services featuring opioid antagonistsnarcotic antagonistspharmaceutical and drug preparations for use in the treatment of opiateopioid or narcotic overdose; online retail pharmacy services
Class 44
Providing medical and health information services; providing a website for patientsmedical professionalspharmacists featuring medical information in the fields of healthmedicineopioids and narcoticsopioid antagonists and narcotic antagonistsdrug overdosesemergency medical tips; providing a website featuring pharmaceutical drug medical information relating to diagnosticprophylactic and therapeutic properties of naloxoneopioid antagonists and narcotic antagonists
Publications
History of USPTO decisions and trademark events.
27 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
06/02/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/11/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/11/2026
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/11/2026
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/11/2026
IUAF
USE AMENDMENT FILED
12/23/2025
EISU
TEAS STATEMENT OF USE RECEIVED
12/23/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
11/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/09/2025
PUBO
PUBLISHED FOR OPPOSITION
09/09/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/03/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/08/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
08/08/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/08/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
08/08/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/08/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/28/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/28/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/28/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/14/2025
GNRT
NON-FINAL ACTION E-MAILED
05/14/2025
CNRT
NON-FINAL ACTION WRITTEN
05/14/2025
DOCK
ASSIGNED TO EXAMINER
05/13/2025
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/11/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/11/2025
NWAP
NEW APPLICATION ENTERED
11/19/2024
Continuous trademark protection
Get notified about every new filing that threatens PADAGIS NALOXONE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.